Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The human immunodeficiency virus (HIV) integrase enzyme is a 32 kDa viral protein essential for the replication of HIV. It catalyzes the integration of viral DNA into the host cell genome, a critical step in the retroviral life cycle that enables persistent infection and viral propagation. Integrase is one of three key enzymes encoded by HIV, alongside reverse transcriptase and protease. Integrase performs two main biochemical reactions during HIV replication: 3'-Processing and Strand Transfer. Because integration is unique to retroviruses like HIV—and absent from normal human cellular processes—integrase represents an attractive drug target. Inhibitors known as integrase strand transfer inhibitors (INSTIs) block this enzyme’s action by interfering with its ability to bind metallic cofactors or interact with substrate DNAs. Resistance can develop through mutations in integrase’s active site regions.
Inhibition of integrase enzyme activity, blocking strand transfer
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Immunodeficiency Virus Integrase Enzyme (Integrase).